Atlas Trials

A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

Clinical trial NCT03362502 · TERMINATED

Trial details

NCT number
NCT03362502
Sponsor
Pfizer
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Duchenne Muscular Dystrophy
Start date
2018-01-23
Primary completion
2022-03-28
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.